Compare Twist Bioscience Corp (TWST) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Unilever plc — how do they compare? Twist Bioscience Corp trades at $156.75 (market cap $10.32B), while Unilever plc trades at $62.29 (market cap $132.07B). The key difference: Unilever plc is far larger — about 12.8× Twist Bioscience Corp's market cap, and Unilever plc pays a 3.48% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Unilever plc for 112 Days on average.
| TWST | UL | |
|---|---|---|
Market Cap | $10.32B | $132.07B |
Volume | 5,894,998 | 2,873,862 |
Sector | Health | Consumer Staples |
52-Week High | $205.00 | $74.59 |
52-Week Low | $25.45 | $55.05 |
Typical Hold Time | 27 Days | 112 Days |
Enterprise Value | $10.24B | $157.21B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Unilever (UL) trades at $61.94, up 1.88% today, amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 18.32% net margins and 54.56% ROE, though recent quarters saw EPS misses. Cash flow turned negative in 2025 at -$2.08B due to increased investing activity. The company is restructuring its portfolio, including the planned $65B food business merger with McCormick, while facing regulatory scrutiny in the UK.
Outlook remains cautious with analyst consensus divided (24% Buy, 51% Hold) and technical indicators bearish. Investment appeal lies in emerging market exposure and dividend stability, but risks include integration challenges from the McCormick deal, competitive pressures, and inconsistent earnings delivery. Valuation at 21.32 P/E appears reasonable given margins but requires execution improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
